Literature DB >> 4061059

Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy.

S Hammarbäck, T Bäckström, J Holst, B von Schoultz, S Lyrenäs.   

Abstract

The etiology of the cyclical mood changes seen in the premenstrual syndrome is still unknown. A close relation to the luteal phase has been shown. One of the differences between the follicular and the luteal phase is the higher plasma progesterone concentration during the luteal phase. The present investigation has been conducted to study the effect of exogenously administered estrogen/gestagen sequential postmenopausal replacement therapy on mood and physical signs. Twenty-two women requiring postmenopausal estrogen treatment were recruited and divided into two groups. Eleven women were given estradiol treatment only (Oestrogel creme 3 mg percutaneously/day) for 21 days with a subsequent break of 7 days. The other 11 women were in addition given progestagen (Lynestrenol, Orgametril 5 mg/day) during the last 11 days of treatment. The women were asked to keep a daily record of their mood, using a visual analogue scale earlier tested in women with premenstrual syndrome. They also kept a record of physical signs and sexual feelings. The records were kept for between one and 6 months. The group with estrogen treatment only did not show any cyclical worsening in mood or physical signs during the treatment. The women who in the latter stage of the estrogen treatment cycle also received progestagen, showed significant cyclicity in both moods and physical signs, with a maximum symptom degree during the final days of gestagen treatment. The negative mood change started 1-3 days after the progestagen was added to the treatment. The results suggest that progestagens are involved in the provocation of cyclical symptom changes seen in the premenstrual syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4061059     DOI: 10.3109/00016348509155154

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  15 in total

1.  Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review.

Authors:  K Wyatt; P Dimmock; P Jones; M Obhrai; S O'Brien
Journal:  BMJ       Date:  2001-10-06

2.  Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.

Authors:  Lotta Andréen; Inger Sundström-Poromaa; Marie Bixo; Sigrid Nyberg; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

Review 3.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

4.  Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study.

Authors:  A L Magos; M Brincat; J W Studd
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-21

Review 5.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder.

Authors:  Ju-Yu Yen; Hung-Pin Tu; Cheng-Sheng Chen; Cheng-Fang Yen; Cheng-Yu Long; Chih-Hung Ko
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-26       Impact factor: 5.270

Review 7.  The role of hormones and hormonal treatments in premenstrual syndrome.

Authors:  Torbjörn Bäckström; Lotta Andreen; Vita Birzniece; Inger Björn; Inga-Maj Johansson; Maud Nordenstam-Haghjo; Sigrid Nyberg; Inger Sundström-Poromaa; Göran Wahlström; Mingde Wang; Di Zhu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

Review 9.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

10.  Effect of zinc supplementation on quality of life and sleep quality in young women with premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Fatemeh Jafari; Mohammad Javad Tarrahi; Armin Farhang; Reza Amani
Journal:  Arch Gynecol Obstet       Date:  2020-06-08       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.